Area of research
Immunology · Dermatology
Research interest
Research interests include Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Spondyloarthritis Studies and Treatments, and Cutaneous lymphoproliferative disorders research.
<i>Staphylococcus aureus</i>induces drug resistance in cancer T cells in Sézary syndrome
Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the <scp>STEPIn</scp> study
Endolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma
Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma
ImmUniverse Consortium: Multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases
Sand, gravel, and UN Sustainable Development Goals: Conflicts, synergies, and pathways forward
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5‒Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma
MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas
<i>Staphylococcus aureus</i> alpha-toxin inhibits CD8 <sup>+</sup> T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma
Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic
Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase <scp>III</scp> clinical trials (re <scp>SURFACE</scp> 1 and re <scp>SURFACE</scp> 2) through 148 weeks
Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4 <sup>+</sup> T cells in cutaneous T-cell lymphoma
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus
SATB1 in Malignant T Cells
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma
STAT5 induces miR-21 expression in cutaneous T cell lymphoma
IκBζ is a key driver in the development of psoriasis
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation
Detection of a Diverse Marine Fish Fauna Using Environmental DNA from Seawater Samples